Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Cancer Drug Shows Promise in… >

Cancer Drug Shows Promise in Eradicating Latent HIV Infection

Published: November 29, 2012.
Released by Federation of American Societies for Experimental Biology  

Bethesda, MD—Breakthrough drugs have made it possible for people to live with HIV longer than ever before, but more work must be done to actually cure the disease. One of the challenges researchers face involves fully eradicating the virus when it is latent in the body. A new report appearing in the December 2012 issue of the Journal of Leukocyte Biology suggests that a cancer drug, called JQ1, may be useful in purging latent HIV infection by activating the virus in the presence of potent therapy – essentially a dead end for the virus.

"This drug may be useful as adjunctive therapy in efforts to purge latent HIV reservoirs to eradicate infection," said Monty A. Montano, Ph.D., principal investigator from the Section of Infectious Diseases at Boston University Medical Campus, in Boston, Mass. "This drug functions synergistically with other HIV purging agents."

To make this discovery, scientists used cell lines that contained latent HIV, as well as cells from patients who were on potent antiretroviral therapy with no detectable virus in their blood. Researchers then added JQ1 to latently infected cells, at physiologic concentrations, and observed potent reactivation of latent HIV. The researchers also observed potent suppression of inflammatory genes in genome-wide expression studies using the same cells. JQ1 reactivation of latent HIV may make it vulnerable to current therapies.

"One thing that's been made clear by the decades of HIV research is that there is no magic bullet for curing this disease," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "Rather, the progress that's been made has been a series of incremental steps that often build on other previously developed therapies. The hope is that the ability of JQ1 to make latent HIV 'visible' to other HIV drugs described in this report will be another cog in the gearwheel of an HIV cure."




The above story is based on materials provided by Federation of American Societies for Experimental Biology.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Hiv 
12/2/14 
★★★★ 
Research Suggests Ability of HIV to Cause AIDS Is Slowing
The rapid evolution of HIV, which has allowed the virus to develop resistance to patients' natural immunity, is at the same time slowing the virus's ability to cause AIDS, …
Cells 
12/19/14 
Cell-associated HIV Mucosal Transmission: The Neglected Pathway
(Boston)--Dr. Deborah Anderson from Boston University School of Medicine (BUSM) and her colleagues are challenging dogma about the transmission of the human immunodeficiency virus type 1 (HIV-1). Most research …
Cells 
11/30/10 
Mayo Researchers Find Drug-resistant HIV Patients with Unimpaired Immune Cells
ROCHESTER, Minn. -- Mayo Clinic researchers have shown why, in a minority of HIV patients, immune function improves despite a lack of response to standard anti-retroviral treatment. In these …
System 
10/16/13 
Elusive Secret of HIV Long-term Immunity
CHICAGO --- Scientists have discovered a critical new clue about why some people are able to control the HIV virus long term without taking antiviral drugs. The finding may …
Transmission 
6/15/12 

Breast Milk Kills HIV And Blocks Its Oral Transmission in Humanized Mouse
Immune 
2/29/12 
Old Drug Reveals New Tricks: Study Shows How the Drug Interferon Works to Suppress Virus
A drug once taken by people with HIV/AIDS but long ago shelved after newer, modern antiretroviral therapies became available has now shed light on how the human body uses …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile